Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional StudyMarie Selvy, David Balayssac, Aurélie Cabrespine et al.|Frontiers in Pharmacology|2021Cited by 53
Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groupsMarie Robin, Jean‐Jacques Kiladjian, Raphaël Porcher et al.|Bone Marrow Transplantation|2021Cited by 32
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide studyJean‐Baptiste Bossard, Jean‐Baptiste Beuscart, Marie Robin et al.|American Journal of Hematology|2020Cited by 24
Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)Enrico Maffini, Mohamad Mohty, Myriam Labopin et al.|Bone Marrow Transplantation|2022Cited by 20
Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional studyFabrice Giraudet, David Balayssac, Marie Selvy et al.|European Archives of Oto-Rhino-Laryngology|2022Cited by 7